Lumbar Degenerative Disc Disease Clinical Trial
— MODELOfficial title:
A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety and Efficacy of SB-01 For Injection for the Treatment of Lumbar Degenerative Disc Disease
The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | June 1, 2025 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. 18 years of age or older 2. Back pain greater than 'worst leg pain' as measured by the NRS 3. Diagnosed with one or two contiguous level(s) lumbar (L1-S1) disc degeneration of Pfirrmann Grade 3 and/or 4 determined by MRI analyzed by the independent radiologic central lab 4. Have chronic low back pain and related disability for at least 6 months with at least 3 months of prior conservative treatment 5. Baseline ODI score = 40/100 6. Baseline NRS = 4 points (Back) 7. Willing and able to provide Informed Consent for study participation 8. Willing and able to comply with this protocol and be available for the entire duration of the study, including ability to access the internet 9. Must practice effective contraception during the first 3 months of follow-up (female of childbearing potential and male subjects): 1. Abstinence or, 2. Surgical Sterilization or, 3. Oral Contraceptives or, 4. Barrier Methods (Condoms, IUD's). 10. Patient must verify that: 1. In the case of females, the patient is post-menopausal or is surgically sterile or, 2. In the case of males, the patient is surgically sterile or, 3. The patient (male or female) confirms that they are at a point in their life where they are beyond consideration of having children. Exclusion Criteria: To qualify for enrollment in this study, patients must meet none of the exclusion criteria as follows. 1. Prior epidural, sacroiliac joint, or facet injections at any lumbosacral level within the past 4 weeks (e.g., transforaminal, interlaminar, caudal) 2. Prior interventional procedures of other types at any lumbosacral level at any time (e.g., intradiscal injection, basivertebral nerve ablation, biacuplasty; radiofrequency (RF) ablation, spinal cord stimulator, others) 3. Prior spine surgery at any lumbosacral level at any time (e.g., discectomy, decompression, instrumentation, fusion, fracture treatment, others) 4. Prior fracture at any lumbar level 5. Significant neurologic symptoms: 1. Grade 3/5 or lower strength in any lumbar myotome 2. Sensory deficit in a clearly radicular or sensory dermatome 6. MRI evidence of disc height loss > 2/3 of adjacent disc at any level to be injected, determined by the independent radiologic central lab 7. MRI evidence of other disc degeneration: Pfirrmann Grade 3-5 at any level not to be injected, determined by the independent radiologic central lab 8. MRI evidence of disc herniation with neural compression at any level, determined by the independent radiologic central lab 9. MRI evidence of significant stenosis of the central canal at any level, determined by the independent radiologic central lab 10. MRI evidence of foraminal stenosis with neural compression at any level, determined by the independent radiologic central lab 11. MRI evidence of moderate-to-severe facet arthrosis with edema at any level, determined by the independent radiologic central lab 12. Spondylolisthesis (antero or retrolisthesis) > 25% at any level, determined by the independent radiologic central lab 13. Lumbar coronal deformity, determined by the independent radiologic central lab: a. L1-S1 regional deformity > 25 degrees 14. Spondylolysis at any level 15. Lumbar inflammatory spondylitis 16. Recent history (previous six months) of chemical or alcohol dependence 17. Chronic narcotic use for more than defined as a daily dose of greater than 40 Morphine Equivalent Units (MEUs) 18. Depression or Somatization defined through the Distress and Risk Assessment Method (DRAM) scoring with Zung score > 33 or Zung > 17 and the Modified Somatic Perception Questionnaire (MSPQ) score > 12 19. Extreme obesity, defined by NIH Clinical Guidelines Body Mass Index (BMI > 40) 20. A QT duration corrected for heart rate by Fridericia's formula (QTcF) > 470 millisecond (msec) 21. Active systemic infection 22. Infection at the site of procedure pre-operatively 23. Cauda equina syndrome or neurogenic bowel/bladder dysfunction 24. Any terminal, systemic, or autoimmune disease including fibromyalgia, which may, in the opinion of the Principal Investigator compromise a subject's ability to comply with study procedures, and/or confound data 25. Metabolic bone disease (e.g., osteoporosis/osteopenia, gout, osteomalacia, Paget's disease) 26. Any disease, condition or surgery which might impair healing, such as: 1. Active malignancy 2. History of metastatic malignancy 27. Currently experiencing an episode of major mental illness (psychosis, major affective disorder, or schizophrenia), or manifesting physical symptoms without a diagnosable medical condition to account for the symptoms, which may indicate symptoms of psychological rather than physical origin 28. Any planned surgical procedure within the subject participation period (screening through the 12 Month Visit) 29. Any clinically relevant laboratory result on the screening visit Chem-12, hematology, or coagulation panels 30. Pregnancy at the time of screening, randomization, or planning to become pregnant during the first 3 months of follow-up 31. Currently a prisoner 32. Participation in any other investigational drug, biologic, or medical device study within the last 6 months prior to study procedure 33. Receiving Work Compensation benefits or engaged in personal spinal injury medical/legal litigation 34. Patient cannot be currently using the prohibited medications listed in the protocol |
Country | Name | City | State |
---|---|---|---|
United States | HD Research | Bellaire | Texas |
United States | Central Alabama Research | Birmingham | Alabama |
United States | Injury Care Research | Boise | Idaho |
United States | Montefiore Medical Center | Bronx | New York |
United States | HD Research at Legent Orthopedic Hospital | Carrollton | Texas |
United States | Pain Management Center, Brigham and Women's Hospital | Chestnut Hill | Massachusetts |
United States | META Medical Research Institute | Dayton | Ohio |
United States | Science Connections, LLC | Doral | Florida |
United States | Clinical Investigations LLC | Edmond | Oklahoma |
United States | NeuroCare Partners | Houston | Texas |
United States | The Orthopaedic Research Foundation, Inc (OrthoIndy) | Indianapolis | Indiana |
United States | Coastal Clinical Research | Jacksonville | Florida |
United States | Kettering Health | Kettering | Ohio |
United States | Neurovations Research | Napa | California |
United States | Duly Health | Naperville | Illinois |
United States | Ainsworth Institute of Pain Management | New York | New York |
United States | Mount Sinai Hospital | New York | New York |
United States | Pioneer Clinical Research | New York | New York |
United States | Vista Clinical Research, LLC | Newnan | Georgia |
United States | Southern California (SC) Spine and Sport Medical Associates, Inc. | Newport Beach | California |
United States | OrthoNebraska | Omaha | Nebraska |
United States | Conquest Research | Orlando | Florida |
United States | Conquest Research | Orlando | Florida |
United States | Four Rivers Clinical Research | Paducah | Kentucky |
United States | Evolve Clinical Research | Phoenix | Arizona |
United States | Virginia iSpine Physicians | Richmond | Virginia |
United States | Pain Relief Centers | Saint Petersburg | Florida |
United States | University of Utah | Salt Lake City | Utah |
United States | Wasatch Clinical Research | Salt Lake City | Utah |
United States | South Texas Spinal Clinic | San Antonio | Texas |
United States | Pacific Research Institute | San Diego | California |
United States | Scripps Health | San Diego | California |
United States | Central Coast Neurological Surgery | San Luis Obispo | California |
United States | Source Healthcare | Santa Monica | California |
United States | Arizona Pain | Scottsdale | Arizona |
United States | Spine Institute of Louisiana | Shreveport | Louisiana |
United States | Florida Pain Relief Group | Tampa | Florida |
United States | Tampa Pain Relief Center | Tampa | Florida |
United States | The Orthopedic Center | Tulsa | Oklahoma |
United States | Precision Spine Care | Tyler | Texas |
United States | Gershon Pain Specialists | Virginia Beach | Virginia |
United States | Tranquil Clinical Research | Webster | Texas |
United States | Abay Neuroscience Center | Wichita | Kansas |
United States | Conquest Research | Winter Park | Florida |
Lead Sponsor | Collaborator |
---|---|
Spine BioPharma, Inc | MCRA |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline in function on the Oswestry Disability Index (ODI) at 6 months. | The ODI is a validated, 10-item self-reported instrument assessment of pain-related disability. Possible scores range from 0 (no disability) - 50 (severe disability). Further calculations are applied to reach a percentage score. | Baseline/Screening and 6 Month | |
Secondary | Change from Baseline in pain on the Numerical Rating Scale (NRS) at 6 months. This outcome will only be tested if the primary endpoint is met. | The NRS is an 11-point scale, self-reported instrument assessment of pain intensity ranging across a continuum from no pain to an extreme amount of pain. The NRS will be collected for: Back and both legs. A lower score indicates less pain. | Baseline/Screening and 6 Month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01198470 -
TRIUMPH Lumbar Artificial Disc IDE: A Pilot Study
|
N/A | |
Terminated |
NCT00744861 -
Ultrasound as Adjunct Therapy for Increasing Fusion Success After Lumbar Surgery
|
N/A | |
Completed |
NCT00949936 -
Safety and Performance Study of the CAdiscTM-L Lumbar Spinal Disc Replacement Device For CE Marking
|
N/A | |
Completed |
NCT03974711 -
Rampart Duo Clinical (RaDical) Post-Market Study
|
||
Recruiting |
NCT01721889 -
Radiostereometric Analysis of Spine Arthrodesis
|
N/A | |
Terminated |
NCT02139527 -
CARES Lumbar Artificial Disc Registry
|
Phase 4 | |
Terminated |
NCT00878579 -
Percutaneous Dynamic Stabilization (PDS) System Versus Fusion for Treating Degenerative Disc Disease
|
Phase 2 | |
Completed |
NCT01640977 -
A Prospective Non-concurrent Controlled Evaluation of Open and MAS® PLIF
|
N/A | |
Terminated |
NCT01689922 -
The Effectiveness of Anti-Gravity Treadmill Training
|
N/A | |
Enrolling by invitation |
NCT02529566 -
Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine
|
N/A | |
Completed |
NCT02347410 -
Spineology Clinical Outcomes Trial: An IDE Investigation
|
N/A | |
Terminated |
NCT02070484 -
Human Amniotic Tissue-derived Allograft, NuCel, in Posteriolateral Lumbar Fusions for Degenerative Disc Disease
|
N/A | |
Terminated |
NCT01294007 -
Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)
|
N/A | |
Terminated |
NCT01293981 -
Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)
|
N/A | |
Terminated |
NCT00640029 -
Evaluation of the Prosthetic Disc Replacement
|
N/A | |
Terminated |
NCT00456378 -
Study of the Safety and Effectiveness of DIAMâ„¢ Spinal Stabilization System Versus Conservative Care
|
N/A | |
Completed |
NCT03647501 -
Lumbar Fusion With Nexxt Spine 3D-Printed Titanium Interbody Cages
|
N/A | |
Active, not recruiting |
NCT02297256 -
Prospective Study of Thoracolumbar Spinal Fusion Graft
|
N/A | |
Completed |
NCT01323387 -
Lumbar Degenerative Disc Disease Treated With Anterior Tension Band System (ATB) With ALIF/FRA Spacer
|
N/A |